Search
Now showing items 1-7 of 7
-
Bacille calmette‐guerin (BCG) vaccine for preventing SARS‐CoV‐2 infection or improving COVID‐19 outcome: evidence review of clinical benefits and harms.
(Wiley & Sons, 2020-05-27)Background: Convalescent plasma and hyperimmune immunoglobulin may reduce mortality in patients with respiratory virus diseases, and are currently being investigated in trials as a potential therapy for coronavirus disease ... -
Remdesivir for COVID‐19: evidence review of the clinical benefit and harm
(South African National Department of Health , 2020-06-24) -
Favipiravir for the prevention and management of COVID‐19: evidence review of the clinical benefit and harm
(South African National Department of Health, 2020-06-25) -
Interleukin‐6 Inhibitor, Tocolizumab, for COVID‐19: evidence review of the clinical benefit and harm
(South African National Department of Health, 2020-04-15) -
Chloroquine and hydroxychloroquine for prevention of COVID‐19: evidence review of clinical benefits and harm
(South African National Department of Health, 2020-06-18) -
Lopinavir–ritonavir (LPV/r) for treatment of COVID‐19: evidence review of clinical benefits and harms
(South African National Department of Health, 2020-04-22) -
Azithromycin for COVID‐19: evidence review of the clinical benefit and harm
(South African National Department of Health , 2020-05-11)